(Q37390730)

20 August 2017

1 reference

title

Postural instability in Parkinson's disease: the adrenergic hypothesis and the locus coeruleus (English)

1 reference

20 August 2017

1 reference

4

Bastiaan R Bloem

1 reference

20 August 2017

3

Raymund A C Roos

1 reference

20 August 2017

Yvette A M Grimbergen

series ordinal

1

1 reference

PubMed ID

19210201

20 August 2017

J William Langston

series ordinal

2

1 reference

20 August 2017

1 February 2009

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

20 August 2017

1 reference

20 August 2017

9

1 reference

20 August 2017

2

1 reference

20 August 2017

279-290

1 reference

The Parkinson's complex: parkinsonism is just the tip of the iceberg

20 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Parkinsonism: onset, progression, and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Prospective assessment of falls in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Medium latency stretch reflexes in young-onset Parkinson's disease and MPTP-induced parkinsonism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

CSF studies on the relationship between dopamine and 5-hydroxytryptamine in Parkinsonism and other movement disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Tremor in Parkinson's disease and serotonergic dysfunction: an 11C-WAY 100635 PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Mild parkinsonism in persons exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Does long-term aggravation of Parkinson's disease result from nondopaminergic lesions?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Postural reflexes in patients on long-term neuroleptic medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Free and supported stance in Parkinson's disease. The effect of posture and 'postural set' on leg muscle responses to perturbation, and its relation to the severity of the disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Medium and long latency EMG responses in leg muscles: Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Bilateral deep brain stimulation of the pedunculopontine nucleus for Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

rCBF changes associated with PPN stimulation in a patient with Parkinson's disease: a PET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

The pedunculopontine nucleus and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

The locus coeruleus and its possible role in ageing and degenerative disease of the human central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Release of neurotransmitters in the locus coeruleus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Quantitation of catecholamine neurons in the locus coeruleus in human brains of normal young and older adults and in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

A Quantitative Study of the Pigmented Neurons in the Nuclei Locus Coeruleus and Subcoeruleus in Man as Related to Aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Efferent projections of nucleus locus coeruleus: morphologic subpopulations have different efferent targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Regional topography within noradrenergic locus coeruleus as revealed by retrograde transport of horseradish peroxidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Initiation and modulation of the locomotor pattern in the adult chronic spinal cat by noradrenergic, serotonergic and dopaminergic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Locus coeruleus and regulation of behavioral flexibility and attention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

The locus coeruleus–noradrenergic system: modulation of behavioral state and state-dependent cognitive processes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Catecholamines and attention. I: Animal and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Convergent regulation of locus coeruleus activity as an adaptive response to stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Vestibular and somatosensory contributions to responses to head and body displacements in stance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Long latency postural responses are functionally modified by cognitive set

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Postural orientation and equilibrium: what do we need to know about neural control of balance to prevent falls?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Postural abnormalities to multidirectional stance perturbations in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Prediction and set-dependent scaling of early postural responses in cerebellar patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Neurological gait disorders in elderly people: clinical approach and classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Disease-specific patterns of locus coeruleus cell loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Stages in the development of Parkinson's disease-related pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Falls and freezing of gait in Parkinson's disease: a review of two interconnected, episodic phenomena

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Cerebrospinal fluid norepinephrine, 3-methoxy-4-hydroxyphenylglycol and neuropeptide Y levels in Parkinson's disease, multiple system atrophy and dementia of the Alzheimer type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Cerebellar norepinephrine in patients with Parkinson's disease and control subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Monoamines and their metabolites in plasma and lumbar cerebrospinal fluid of Chinese patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Imaging non-dopaminergic function in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Noradrenergic drugs for levodopa-induced dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Endogenous restoration of noradrenaline by precursor therapy in dopamine-beta-hydroxylase deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Differential effect of L-threo-3,4-dihydroxyphenylserine in pure autonomic failure and multiple system atrophy with autonomic failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Formation of noradrenaline in the rat brain from the four stereoisomers of 3,4-dihydroxyphenylserine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Increase in norepinephrine turnover after tyrosine or DL-threo-3,4-dihydroxyphenylserine (DL-threo-DOPS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

L-threo-3,4-dihydroxyphenylserine, a noradrenaline precursor, inhibits dopamine release and metabolism in the rat striatum in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Idazoxan treatment in progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Can methylphenidate reduce fall risk in community-living older adults? A double-blind, single-dose cross-over study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Effects of methylphenidate on cognitive function and gait in patients with Parkinson's disease: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Aminergic systems in Alzheimer's disease and Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Concentrations of indoleamine metabolic intermediates in the ventricular cerebrospinal fluid of advanced Parkinson's patients with severe postural instability and gait disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Associated postural adjustments in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Step initiation in Parkinson's disease: influence of levodopa and external sensory triggers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

Biogenic amines and metabolites in spinal cord of patients with Parkinson's disease and amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.2.279

21 January 2018

Identifiers

DOI

10.1586/14737175.9.2.279

1 reference

20 August 2017

1 reference

PubMed ID

19210201